Aspartame and citrate flavored phosphate salt laxative

Details Aspartame and citrate flavored phosphate salt laxative Aspartame and citrate flavored phosphate salt laxative

2011-01-11

2011-01-11

Arnold, Ernst V (Department: 1613)

Drug, bio-affecting and body treating compositions

Inorganic active ingredient containing

Phosphorus or phosphorus compound

C424S601000

Reexamination Certificate

active

07867521

ABSTRACT:
The present invention provides compositions, kits, and methods suitable for cleansing the colon before colonoscopy. The compositions include a phosphate salt and a flavorant that includes aspartame and a citrate. The kits include the previously mentioned compositions and also may include suitable containers, packaging, relief wipes, and instructions for use. The methods may include administering orally to a subject an aqueous preparation including monobasic sodium phosphate, dibasic sodium phosphate, aspartame, and citric acid.

REFERENCES:
patent: H859 (1990-12-01), Augustine
patent: 5013716 (1991-05-01), Cherukuri et al.
patent: 5106632 (1992-04-01), Wong et al.
patent: 5124144 (1992-06-01), Giorgetti et al.
patent: 5274001 (1993-12-01), Borody
patent: 5498425 (1996-03-01), Wood et al.
patent: 5616346 (1997-04-01), Aronchick
patent: 5688529 (1997-11-01), Lidgate et al.
patent: 5997906 (1999-12-01), Wood et al.
patent: 6103268 (2000-08-01), Borody et al.
patent: 6156332 (2000-12-01), Bakal et al.
patent: 6162464 (2000-12-01), Jacob et al.
patent: 6361799 (2002-03-01), Palkhiwala
patent: 6737068 (2004-05-01), Durden
patent: 6806256 (2004-10-01), Ulrich et al.
patent: 6866873 (2005-03-01), Stern
patent: 6906038 (2005-06-01), Mazer
patent: 6946149 (2005-09-01), Cleveland
patent: 7101572 (2006-09-01), Santos et al.
patent: 7169381 (2007-01-01), Barras et al.
patent: 7332184 (2008-02-01), Vanner et al.
patent: 2002/0137803 (2002-09-01), Kirkland
patent: 2004/0071779 (2004-04-01), Keiser et al.
patent: 2004/0101491 (2004-05-01), Stier
patent: 2004/0115282 (2004-06-01), Keiser et al.
patent: 2004/0143005 (2004-07-01), Barras et al.
patent: 2004/0170698 (2004-09-01), Halow
patent: 2004/0192614 (2004-09-01), Vanner et al.
patent: 2005/0061861 (2005-03-01), Pennino
patent: 2005/0271749 (2005-12-01), Borody et al.
patent: 2006/0051428 (2006-03-01), Ayala et al.
patent: 2007/0082061 (2007-04-01), Ayala et al.
patent: 2007/0207216 (2007-09-01), Caswell
patent: 2008/0044489 (2008-02-01), Caswell
patent: 2008/0145445 (2008-06-01), Ayala et al.
patent: 541665 (1959-08-01), None
patent: 0396165 (1990-11-01), None
patent: WO89/05659 (1989-06-01), None
patent: WO 93/17589 (1993-09-01), None
patent: WO 94/12191 (1994-06-01), None
patent: WO 98/43654 (1998-10-01), None
patent: WO 2004/032926 (2004-04-01), None
patent: WO 2004/037292 (2004-05-01), None
patent: WO 2006/028632 (2006-03-01), None
patent: WO 2006/118562 (2006-11-01), None
patent: WO 2007/044681 (2007-04-01), None
Rao, “Toxicologic Pathology of the Kidney and Urinary Bladder,” Toxicologic Pathology, vol. 30, No. 6, pp. 651-656, 2002.
Vanner et al., “A Randomized Prospective Trial Comparing Oral Sodium Phosphate with Standard Polyethylene Glycol-Based Lavage Solution (Golytely) in the Preparation of Patients for Colonoscopy,” The American Journal of Gastroenterology, vol. 85, No. 4, pp. 422-427, 1990.
Toblli et al., “Potassium citrate administration ameliorates tubulointerstitial lesions in rats with uric acid nephropathy,” Clinical Nephrology, vol. 55, No. 1, pp. 59-68, 2001.
Lacour et al., “Ellet du citrate et des phosphate sur le transport du calcium dans l'iléon de rat in vitro,” Gastroenterol Clin. Biol., 18, pp. 938-944, 1994. (Summary in English).
Oikawa et al., “Modulation of plasminogen activator inhibitor-1 in vivo : A new mechanism for the anti-fibrotic effect of rennin-angiotensin inhibition,” Kidney International, vol. 51, pp. 164-172, 1997.
Marangella et al., “Crystallization Inhibitors in the Pathophysiology and Treatment of Nephrolithiasis,” Urologia Int., 72, Suppl. 1, pp. 6-10, 2004.
Neuhofer et al., “Chronic COX-2 inhibition reduces medullary HSP70 expression and induces papillary apoptosis in dehydrated rats,” Kidney International, vol. 65, pp. 431-441, 2004.
Ma et al., “Model of robust induction of glomerulosclerosis in mice: Importance of genetic background,” Kidney International, vol. 64, pp. 350-355, 2003.
Smoyer et al., “Ischemic Acute Renal Failure Induces Differential Expression of Small Heat Shock Proteins,” J Am Soc Nephrol, 11, pp. 211-221, 2000.
Desmeules et al., “Acute Phosphate Nephropathy and Renal Failure,” NEJM, 349, pp. 1006-1007, 2003.
Markowitz et al., “Acute Phosphate Nephropathy following Oral Sodium Phosphate Bowel Purgative: An Underrecognized Cause of Chronic Renal Failure,” J Am Soc Nephrol, 16, pp. 3389-3396, 2005.
Markowitz et al., “Renal Failure Due to Acute Nephrocalcinosis Following Oral Sodium Phosphate Bowel Cleansing,” Human Pathology, 35, 675-684, 13 pages total, 2004.
Ritskes-Hoitinga et al., “Phosphorus-Induced Nephrocalcinosis and Kidney Function in Female Rats,” J. Nutr., 119, pp. 1423-1431, 1989.
Orias et al., “Extreme Hyperphosphatemia and Acute Renal Failure after a Phosphorus-Containing Bowel Regimen,” Am J Nephrol, 19, pp. 60-63, (1999).
Fine et al., “Severe Hyperphosphatemia Following Phosphate Administration for Bowel Preparation in Patients With Renal Failure: Two Cases and a Review of the Literature,” American Journal of Kidney Diseases, vol. 29, No. 1, pp. 103-105, (1997).
Wangoo et al., “Chronobiology of urinary citrate excretion amongst stone-fomers and healthy males from North Western India”, Urological Research, 19:203-206, (1991).
Moeckel et al, “Distribution of de novo synthesized betaine in rat kidney: role of renal synthesis on medullary betaine accumulation,” Am. J. Physiol., 272, pp. F94-F99, (1997).
Moeckel et al, “COX2 Activity Promotes Organic Osmolyte Accumulation and Adaptation of Renal Medullary Interstitial Cells to Hypertonic Stress,” Journal of Biological Chemistry, vol. 278, No. 21, pp. 19352-19357, (2003).
Moeckel et al., “Role of integrin α1β1in the regulation of renal medullary osmolyte concentration,” Am J Physiol Renal Physiol, 290, pp. F223-F231, (2006).
Marshall et al., “Prospective, randomized trial comparing sodium phosphate solution with polyethylene glycol-electrolyte lavage for colonoscopy preparation,” Gastrointestinal Endoscopy, vol. 39, No. 5, pp. 631-634, (1993).
Petsite.com Ltd., “Amazing Rodent Facts,” located at http://www.petalia.com.au/templates/StoryTemplate—Process.cfm?Story—No=350, p. 1, printed Nov. 2007.
Nie et al., “Distinct Contributions of T1R2 and T1R3 Taste Receptor Subunits to the Detection of Sweet Stimuli,” Current Biology, vol. 15, pp. 1948-1952, (2005).
International Food Information Council Foundation, “Everything You Need to Know About Sucralose,” 2 pages, (1998).
International Food Information Council Foundation, “Everything You Need to Know About Acesulfame Potassium,” 2 pages, (1998).
Calorie Control Council, “Low-Calorie Sweeteners: Acesulfame Potassium,” can be found at http://www.caloriecontrol.org/acesluf.html, 3 pages, (2004).
International Food Information Council Foundation, “Low-Calorie Sweeteners:Adding Reduced-Calorie Delights to a Healthful Diet,” can be found at http://www.ific.org/foodinsight/1998/jf/lcsfi198.cfm?renderforprint=1, 4 pages, (1998).
International Food Information Council Foundation, “More Choices For The Sweet Life,” can be found at http://www.ific.org/foodinsight/2002/so/morechoicesfi502.cfm?renderforprint=1, 3 pages, (2002).
FoodProductionDaily.com/Europe, “Sweet taste study promises perfect sugar replacement,” can be found at http://www.foodproductiondaily.com
ews/printNewsBis.asp?id=63743, 2 pages, (2005).
International Search Report dated Mar. 29, 2007 for application No. PCT/US2006/039419.
Khashab, M. et al., “Efficacy and tolerability of a new formulation of sodium phosphate tablets (INKP-101), and a reduced sodium phosphate dose, in colon cleansing: a single-center open-label pilot trial”, Aliment Pharmacol Ther., vol. 21, pp. 465-468, (2005).
R

Affiliated with

Also associated with

Rating

Aspartame and citrate flavored phosphate salt laxative does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aspartame and citrate flavored phosphate salt laxative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aspartame and citrate flavored phosphate salt laxative will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2725721